Boston Cambridge Biotech Networks

BCBN Feed: NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price https://lnkd.in/gRKa6PgG CAMBRIDGE, Mass., Dec. 2, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced the entry into a definitive agreement with a single... ... [...]

BCBN Feed: ConcertAI Announces Cloud-Based SaaS Transformation of TeraRecon Portfolio, Expanding its AI-Enhanced Clinical Capabilities in Medical Imaging https://lnkd.in/gqkfE6Dr CAMBRIDGE, Mass. & CHICAGO--(BUSINESS WIRE)--ConcertAI, the leader in predictive and generative AI SaaS and DaaS solutions for healthcare and life sciences, today announced a Software-as-a-Service (SaaS) cloud version of TeraRecon’s AI-enabled portfolio of advanced visualization (AV) and generative AI modules for clinical workflows. This is a milestone in making the... ... [...]

BCBN Feed: Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer https://lnkd.in/gwaPMWsi SHANGHAI & CAMBRIDGE, Mass. & ROOT, Switzerland--(BUSINESS WIRE)--Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) and Novocure (NASDAQ: NVCR) announced today that the pivotal, Phase 3 PANOVA-3 trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival (mOS) versus control. PANOVA-3 evaluated the use of Tumor Treating... ... [...]

BCBN Feed: Hologic Presents New Research Demonstrating How Its Breast Imaging AI Solution Performs Similarly Across Diverse Populations https://lnkd.in/g2UdHZhf MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #AI--Hologic Presents New Research Demonstrating How Its Breast Imaging AI Solution Performs Similarly Across Diverse Populations ... [...]

BCBN Feed: Radioactive particles in air pollution linked with worse survival in lung cancer patients https://lnkd.in/gN6yHQhh Exposure to a type of ionizing radiation associated with particulate air pollution—called ambient beta particle radioactivity—may lower chances of survival among lung cancer patients, according to a new Harvard Chan School study. ... [...]

BCBN Feed: Ten Companies to Watch in AI Drug Discovery https://lnkd.in/d9AP7GRA In AI-based drug discovery—a field benefiting from a cumulative investment of $60 billion—the leaders are making real progress toward approved therapies. The post Ten Companies to Watch in AI Drug Discovery appeared first on GEN - Genetic Engineering and Biotechnology News. ... [...]

BCBN Feed: Apogee Therapeutics Announces Agenda for Virtual R&D Day https://lnkd.in/dxfNBKnM SAN FRANCISCO and WALTHAM, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive... ... [...]

BCBN Feed: “LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in South Korea https://lnkd.in/giaTMzaD TOKYO and CAMBRIDGE, Mass., Nov. 27, 2024 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the humanized... ... [...]

BCBN Feed: Targeting “Proteolethargy” to Restore Protein Mobility May Represent Therapeutic Approach for Chronic Diseases https://lnkd.in/gAFA-wc6 Researchers found that many chronic diseases exhibit reduced protein mobility—proteolethargy—as a common denominator that could be driving cellular dysfunction. Their studies linked proteolethargy to a dysregulated redox environment and suggested a therapeutic strategy. The post Targeting “Proteolethargy” to Restore Protein Mobility May Represent Therapeutic Approach for Chronic Diseases appeared... ... [...]

BCBN Feed: mRNA therapy reduced scar tissue in rabbits with post-surgery eye condition https://lnkd.in/gZd57rq5 Proliferative vitreoretinopathy (PVR) is an eye condition that leads to blindness and can currently only be addressed with surgery. A team led by research hospital Massachusetts Eye and Ear and German biotech CureVac has designed an mRNA therapy that delivered a therapeutic gene transcript to the eyes of rabbits... ... [...]